Condition
Moderate to Severe Traumatic Brain Injury
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Completed2
Recruiting1
Unknown1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07481656Phase 4Not Yet Recruiting
Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT)
NCT06062888Phase 2RecruitingPrimary
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
NCT03874416Not ApplicableUnknownPrimary
Cognitive Rehabilitation of Working Memory After Moderate to Severe Traumatic Brain Injury
NCT03143751Phase 3CompletedPrimary
Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients
NCT01250132Not ApplicableCompletedPrimary
Ante-hypophyseal Dysfunctions in Children Following Moderate to Severe Traumatic Brain Injuries
Showing all 5 trials